Atta Chowdhry, RPh, opens a discussion surrounding prophylactic treatment in patients diagnosed with hemophilia A.

An array of complications may arise associated with treatment of hemophilia A.

Atta Chowdhry, RPh, discusses challenges with factor replacement therapy in patients with hemophilia A.

Atta Chowdhry, RPh, explores the burdens associated with hemophilia A.

Cost strategies impacting the treatment landscape in hemophilia, like reimbursement rates , are discussed by a medical expert .

Atta Chowdhry, RPh, shares his final thoughts regarding the trajectory of hemophilia treatment strategies.

The standard treatment strategies for hemophilia A are explored by Lisa Schrade, PharmD.

Dr Schrade discusses the impact of prophylactic treatment for patients with hemophilia A.

Extended half-life factor products are key contributors to successful hemophilia A treatment pathways.

Lisa Schrade, PharmD, shares insight on the impact of inhibitors in the hemophilia A treatment landscape.

In her closing thoughts , Lisa Schrade, PharmD, discusses current barriers to care as well as the upcoming direction of treatment for patients with hemophilia A.